OctoPlus, Novartis Collaborate On PolyActive Drug Delivery Technology
As per the agreement, OctoPlus is expected to develop, making use of its PolyActive technology, in-vivo feasibility, a controlled release formulation of an undisclosed compound. Novartis is expected
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.